[Positive ventriculography with metrizamide (Amipaque)(author's transl)].
Our experience with the water-soluble contrast medium metrizamide (Amipaque) for ventriculography is described. No significant side effects were observed in our 27 patients, of whom 12 were children. A mild increase in CSF cell count disappeared after a few days. In 24 of the 27 patients, very good or adequate, and in any case diagnostic, information was obtained regarding the third and fourth ventricles, aqueduct, as well as sometimes the basal cisterns and outline of the cerebellum.
D000293:Adolescent; D000328:Adult; D002551:Cerebral Ventricle Neoplasms / Q000000981:diagnostic imaging; D014695:Cerebral Ventriculography / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003397:Craniopharyngioma / Q000000981:diagnostic imaging; D005260:Female; D006392:Hemangioma, Cavernous / Q000000981:diagnostic imaging; D006801:Humans; D006849:Hydrocephalus / Q000000981:diagnostic imaging; D007223:Infant; D008297:Male; D008527:Medulloblastoma / Q000000981:diagnostic imaging; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D009442:Neurilemmoma / Q000000981:diagnostic imaging
D008793:Metrizamide
Die positive Ventrikulographie mit Metrizamide (Amipaque).